They further showed that luteolin exerts its anti-tumorigenic action by blocking the phosphorylation of YBX1 by RSK, leading to reduced growth of triple-negative breast cancer cells as well as its tumor-initiating cells [68]. This evidence concerns the gene YBX1 and neoplasm.